US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,642.04

-6.3094-0.38%

Number of Gainers:4

Number of Losers:6

Number of Flat:1

PE:- -

High:1,657.78

Open:1,648.36

Low:1,630.16

Close:1,648.35

Volume:17.11M

Turnover:839.29M

Market Cap:183.14B

Float Cap:182.37B

Loading ...

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Quest Diagnostics : Barclays Raises Target Price to $195 From $190

THOMSON REUTERS

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Stryker (SYK) and Quest Diagnostics (DGX)

DiaSorin Signs Agreement to Supply LIAISON PLEX Systems to Quest Diagnostics

Quest Diagnostics Reports Strong Q3 2025 Results

Quest Diagnostics Drops 3.1% in Tuesday's Late Trading

Quest Diagnostics Exec Says More Likelihood of Pama Delay Than Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act Passing

THOMSON REUTERS

Quest Diagnostics Exec Says Utilization Levels Will Continue in Q4 as We've Seen Them in Q3 - Conf Call

THOMSON REUTERS

Inovio Reports Positive Phase 1 Results for DNA-Encoded Monoclonal Antibodies Against COVID-19

Quest Diagnostics raises annual profit and revenue forecasts on lab test demand

Quest Diagnostics Lifts Guidance on Organic Growth

Quest Diagnostics Shares up 2.7% Premarket After Q3 Beat

THOMSON REUTERS

Health Canada Approves Gilead’s LYVDELZI for Primary Biliary Cholangitis

Lyvdelzi® (Seladelpar) Receives Health Canada Approval for the Treatment of Primary Biliary Cholangitis

THOMSON REUTERS

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Quest Diagnostics Q3 revenue beats estimates on higher demand

BRIEF-Quest Diagnostics Q3 Adjusted EPS USD 2.6 Vs. IBES Estimate USD 2.5

Quest Diagnostics reports third quarter revenue of $2.82 billion and diluted EPS of $2.16

Quest Diagnostics Outlook FY Adjusted EPS USD 9.76-9.84

THOMSON REUTERS

Quest Diagnostics Outlook FY EPS USD 8.58-8.66

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4583/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1642.0446,"timestamp":1761595199999,"preClose":1648.354,"halted":0,"volume":17110041,"delay":0,"changeRate":-0.003828,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-6.309448,"latestTime":"10-27 16:00:00 EDT","open":1648.3593,"high":1657.784,"low":1630.1554,"amount":839288024.44297,"amplitude":0.016761,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1761609600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.225834,"peRate":48.063818,"turnoverRate":0.006415,"increases":4,"decrements":6,"flats":0,"marketCap":183135774842.25,"floatMarketCap":182373102366.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1657.784,"amplitude":0.016761,"preClose":1648.354,"low":1630.1554,"pbRate":"4.225834","latestPrice":1642.0446,"volume":17110041,"delay":0,"open":1648.3593,"prevYearClose":1284.7982,"prevWeekClose":1648.354,"prevMonthClose":1540.8464,"prevQuarterClose":1540.8464,"fiveDayClose":1680.6075,"twentyDayClose":1554.3335,"sixtyDayClose":1523.7755,"secType":"PLATE","market":"US","turnoverRate":0.006415,"peRate":48.063818,"marketCap":183135774842.25,"floatMarketCap":182373102366.5,"timestamp":1761595199999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":4,"down":6,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577636539","title":"Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2577636539","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577636539?lang=en_us&edition=fundamental","pubTime":"2025-10-22 19:00","pubTimestamp":1761130800,"startTime":"0","endTime":"0","summary":"FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3170937/28908/en/Tonix-Pharmaceuticals-Announces-First-Patient-Dosed-in-the-Investigator-Initiated-FOCUS-Study-of-Tonix-s-Intranasal-Potentiated-Oxytocin-in-AVP-D-Conducted-by-Massachusetts-General.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HI","TNXP","LU2125154935.USD","AVP","CNS","LU2360032135.SGD","BK4135","BK4139","BK4583","LU0029874061.USD","BK4161","LU2125154778.USD","LU0128526141.USD"],"gpt_icon":0},{"id":"2577521323","title":"Quest Diagnostics : Barclays Raises Target Price to $195 From $190","url":"https://stock-news.laohu8.com/highlight/detail?id=2577521323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577521323?lang=en_us&edition=fundamental","pubTime":"2025-10-22 17:39","pubTimestamp":1761125948,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nAZN4OUOFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DGX","BK4588","BK4567","BK4196","LU1854103824.USD","LU1854104046.USD","BK4585","BK4583"],"gpt_icon":0},{"id":"2577567403","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Stryker (SYK) and Quest Diagnostics (DGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2577567403","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577567403?lang=en_us&edition=fundamental","pubTime":"2025-10-22 16:10","pubTimestamp":1761120645,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Stryker (SYK – Research Report) and Quest Diagnost...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-stryker-syk-and-quest-diagnostics-dgx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-stryker-syk-and-quest-diagnostics-dgx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU2404859741.USD","BK4567","BK4566","BK4196","GB00B4QBRK32.GBP","HCSG","LU1854104046.USD","LU2362541273.HKD","BK4137","LU0029874061.USD","LU1791710582.SGD","DGX","LU2089984988.USD","LU0690374615.EUR","BK4082","LU0882574055.USD","SYK","LU0058720904.USD","BK4581","LU2468319806.SGD","LU0432979614.USD","LU2362540622.SGD","LU2404859667.USD","LU0114720955.EUR","XLV","XBI","LU1854103824.USD","LU1791710400.SGD","BK4504","GB00B4LPDJ14.GBP","LU0128526141.USD","LU0528227936.USD","LU0690374961.EUR","BK4585","LU1983299246.USD","LU2324357040.USD","LABU","LU2362541513.USD","BK4583","LU0289739699.SGD"],"gpt_icon":0},{"id":"2577328323","title":"DiaSorin Signs Agreement to Supply LIAISON PLEX Systems to Quest Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2577328323","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577328323?lang=en_us&edition=fundamental","pubTime":"2025-10-22 13:46","pubTimestamp":1761111970,"startTime":"0","endTime":"0","summary":"DiaSorin S.p.A. has announced the signing of a supplier agreement with Quest Diagnostics, a provider of diagnostic information services in the United States. Under the terms of the agreement, DiaSorin will deploy 24 LIAISON PLEX systems across eight Quest Diagnostics laboratories in the U.S. The agreement also includes the supply of the LIAISON PLEX Respiratory Panel to meet demand for respiratory testing during the upcoming flu season. This arrangement aims to expand access to advanced molecular multiplexing technology in the Quest Diagnostics laboratory network.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaSorin S.p.A. published the original content used to generate this news brief on October 22, 2025, and is solely responsible ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDLcdFbQz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","LU0472753341.HKD","LU0124676726.USD","LU0069063385.USD","LU1854103824.USD","BK4096","ROK","LU0689626769.HKD","LU1064131342.USD","DGX","BK4588","BK4567","BK4583","LU1988902786.USD","LU1894683348.USD","LU0289739343.SGD","LU0511384066.AUD","LU0289961442.SGD","LU1894683264.USD","BK4585","LU2264538146.SGD","BK4196","LU0057025933.USD","LU0154245673.USD","BK4580","LU0390134368.USD","LU0154245756.USD"],"gpt_icon":0},{"id":"2577333645","title":"Quest Diagnostics Reports Strong Q3 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2577333645","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577333645?lang=en_us&edition=fundamental","pubTime":"2025-10-22 12:03","pubTimestamp":1761105810,"startTime":"0","endTime":"0","summary":"Quest Diagnostics ( ($DGX) ) has released its Q3 earnings. Here is a breakdown of the information Quest Diagnostics presented to its investors. Que...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quest-diagnostics-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quest-diagnostics-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1854103824.USD","BK4583","BK4196","DGX","BK4585","BK4588","BK4567","LU1854104046.USD"],"gpt_icon":0},{"id":"1175942366","title":"Quest Diagnostics Drops 3.1% in Tuesday's Late Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1175942366","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175942366?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:00","pubTimestamp":1761076817,"startTime":"0","endTime":"0","summary":"In the late trading session on Tuesday, Quest Diagnostics (DGX) saw a decline of 3.1%. Key takeaways from the company's Q3 2025 earnings call highlight strong revenue growth and strategic investments driving performance.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DGX","LU1854103824.USD","BK4583","LU1854104046.USD","BK4588","BK4196","BK4585","BK4567"],"gpt_icon":0},{"id":"2577873835","title":"Quest Diagnostics Exec Says More Likelihood of Pama Delay Than Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act Passing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577873835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577873835?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:52","pubTimestamp":1761051122,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nFWN3W12UB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DGX","BK4585","LU1854104046.USD","BK4588","LU1854103824.USD","BK4567","BK4196","BK4583"],"gpt_icon":0},{"id":"2577704878","title":"Quest Diagnostics Exec Says Utilization Levels Will Continue in Q4 as We've Seen Them in Q3 - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2577704878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577704878?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:52","pubTimestamp":1761051122,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nFWN3W12UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","LU1854103824.USD","LU1854104046.USD","BK4585","BK4588","BK4196","DGX","BK4567"],"gpt_icon":0},{"id":"2577827709","title":"Inovio Reports Positive Phase 1 Results for DNA-Encoded Monoclonal Antibodies Against COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2577827709","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577827709?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:05","pubTimestamp":1761048323,"startTime":"0","endTime":"0","summary":"Inovio Pharmaceuticals Inc. has announced results from a Phase 1 proof-of-concept clinical trial evaluating DNA-encoded monoclonal antibodies  for COVID-19. The results, now published in Nature Medicine, include data from all 39 participants up to week 72 of follow-up. The study demonstrated durable and tolerable expression of DMAbs, with effective target binding and confirmed functional activity through week 72. No immune rejection or anti-drug antibodies were detected in approximately 1,000 blood samples. The most common side effects reported were mild and temporary injection site reactions, such as pain and redness. No serious adverse events related to the study drug were observed. Further exploratory analyses of clinical samples are ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL8Slnlf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INO","BK4583","BK4139","BK4568"],"gpt_icon":0},{"id":"2577824303","title":"Quest Diagnostics raises annual profit and revenue forecasts on lab test demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2577824303","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577824303?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:12","pubTimestamp":1761045160,"startTime":"0","endTime":"0","summary":"Quest Diagnostics raises annual profit and revenue forecasts on lab test demandOct 21 (Reuters) - Laboratory operator Quest Diagnostics DGX.N raised its full-year forecast for profit and revenue on Tu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nL4N3W10P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU1854103824.USD","LU0251142724.SGD","LU0251131958.USD","LU1854104046.USD","BK4585","BK4588","LU0006061336.USD","LU0048573561.USD","LH","BK4196","DGX","BK4567","BK4550","LU1059921491.USD","LU0742534661.SGD"],"gpt_icon":0},{"id":"2577182458","title":"Quest Diagnostics Lifts Guidance on Organic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2577182458","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577182458?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:12","pubTimestamp":1761045120,"startTime":"0","endTime":"0","summary":"Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter.The provider of diagnostic information services said Tuesday that organic revenue growth in the latest completed quarter hit 6.8%, while acquisitions boosted the top line higher.Quest is now guiding for $10.96 billion to $11 billion in revenue for 2025, up from a prior outlook for $10.8 billion to $10.92 billion, and adjusted earnings of $9.76 to $9.84 a share, up from $9.63 to $9.83 a share.Shares advanced 2.4% to $195 in premarket trading.For the third quarter, the Secaucus, N.J., company posted a profit of $245 million, or $2.16 a share, compared with $226 million, or $1.99 a share, in the same quarter a year earlier.Stripping out one-time items, adjusted earnings were $2.60 a share, topping analyst forecasts by a dime, according to FactSet.Revenue jumped 13% to $2.82 billion, ahead of analyst estimates for $2.74 bill","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4196","LU1854103824.USD","BK4585","DGX","LU1854104046.USD","BK4583","BK4567"],"gpt_icon":0},{"id":"2577442821","title":"Quest Diagnostics Shares up 2.7% Premarket After Q3 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2577442821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577442821?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:02","pubTimestamp":1761044536,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nL4N3W20OA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4567","BK4588","LU1854104046.USD","BK4583","BK4196","BK4585","LU1854103824.USD","DGX"],"gpt_icon":0},{"id":"2577821291","title":"Health Canada Approves Gilead’s LYVDELZI for Primary Biliary Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2577821291","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577821291?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:01","pubTimestamp":1761044477,"startTime":"0","endTime":"0","summary":"Gilead Sciences Inc. has announced that Health Canada has approved LYVDELZI  for the treatment of primary biliary cholangitis . The approval allows LYVDELZI to be used in combination with ursodeoxycholic acid  in adults who have had an inadequate response to UDCA alone, or as monotherapy for those unable to tolerate UDCA. This conditional market authorization is based on data from the Phase 3 RESPONSE study, where LYVDELZI demonstrated statistically significant and durable improvements in both pruritus and markers of cholestasis, addressing unmet needs in the PBC patient community. The approval is pending the results of ongoing trials to further verify its clinical benefit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDLVtfxp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU2089984988.USD","LU1674673691.USD","BK4578","LU0882574055.USD","LU2468319806.SGD","LU0234570918.USD","BK4583","LU0058720904.USD","BK4550","LU1430594728.SGD","LU0289739699.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","IE0002270589.USD","LU0320765992.SGD","LU1839511570.USD","BK4139","GILD","LU1585245621.USD","LU1778281490.HKD","LU0823416689.USD","LU2087621335.USD","BK4568","BK4566","LU0889565916.HKD","IE00B7SZLL34.SGD","LU1066053197.SGD","IE00BSNM7G36.USD","IE00BKVL7J92.USD","SG9999015945.SGD","LU0109394709.USD","LU1674673428.USD","LU1571399168.USD","BK4588","SG9999015986.USD","LU2324357040.USD","SG9999015952.SGD","BK4585","IE00B19Z3B42.SGD","SG9999015978.USD","LU0114720955.EUR","IE00BZ1G4Q59.USD","BK4532"],"gpt_icon":0},{"id":"2577211798","title":"Lyvdelzi® (Seladelpar) Receives Health Canada Approval for the Treatment of Primary Biliary Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2577211798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577211798?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:00","pubTimestamp":1761044401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nTUA6HDH0M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1571399168.USD","SG9999015945.SGD","LU0058720904.USD","LU0234570918.USD","LU1674673691.USD","IE00BZ1G4Q59.USD","LU2087621335.USD","LU1674673428.USD","LU0289739699.SGD","LU0889565916.HKD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU1066051498.USD","LU2468319806.SGD","BK4566","LU1066053197.SGD","BK4550","IE00B3T34201.USD","SG9999015952.SGD","SG9999015986.USD","LU1430594728.SGD","LU1585245621.USD","BK4532","LU2324357040.USD","LU0320765992.SGD","LU0109394709.USD","LU0114720955.EUR","IE00BKVL7J92.USD","BK4588","GILD","LU0882574055.USD","BK4583","SG9999015978.USD","BK4578","LU2089984988.USD","LU0823416689.USD","LU1839511570.USD","BK4585","IE0002270589.USD","IE00B19Z3581.USD","LU1778281490.HKD","BK4139","BK4568","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2577820814","title":"Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2577820814","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577820814?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:00","pubTimestamp":1761044400,"startTime":"0","endTime":"0","summary":"CHATHAM, N.J., Oct.  21, 2025  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/21/3170047/28908/en/Tonix-Pharmaceuticals-to-Present-Poster-on-Tonmya-at-the-2025-American-College-of-Rheumatology-ACR-Convergence.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154778.USD","BK4161","TNXP","BK4110","HI","BK4117","LU2360032135.SGD","BK4135","BK4107","AFG","LU0128526141.USD","BK4139","BK4583","CNS","ACR","LU0029874061.USD","LU2125154935.USD"],"gpt_icon":0},{"id":"2577982130","title":"Quest Diagnostics Q3 revenue beats estimates on higher demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2577982130","media":"Reuters","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577982130?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:54","pubTimestamp":1761044047,"startTime":"0","endTime":"0","summary":"Quest Diagnostics Q3 revenue beats estimates on higher demandOverviewQuest Diagnostics Q3 revenue rises 13.1%, beating analyst expectationsAdjusted EPS for Q3 beats consensus, reflecting strong operat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nL1N3W20BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4583","DGX","LU1854103824.USD","BK4588","BK4585","LU1854104046.USD","BK4567"],"gpt_icon":0},{"id":"2577182949","title":"BRIEF-Quest Diagnostics Q3 Adjusted EPS USD 2.6 Vs. IBES Estimate USD 2.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2577182949","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577182949?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:45","pubTimestamp":1761043546,"startTime":"0","endTime":"0","summary":"Oct 21  - Quest Diagnostics Q3 net income USD 245 million.Q3 revenue USD 2,816 million vs. IBES estimate USD 2,734 million. QUEST DIAGNOSTICS OUTLOOK FY REVENUE USD 10,960-11,000 MILLION","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nPLX7ED46A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","DGX","BK4585","BK4567","BK4196","LU1854103824.USD","LU1854104046.USD","BK4583"],"gpt_icon":0},{"id":"2577829289","title":"Quest Diagnostics reports third quarter revenue of $2.82 billion and diluted EPS of $2.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2577829289","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577829289?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:45","pubTimestamp":1761043533,"startTime":"0","endTime":"0","summary":"Quest Diagnostics Incorporated reported third quarter 2025 revenues of $2.82 billion, an increase of 13.1% compared to the same period in 2024. Operating income for the quarter was $458 million, up 18.9% from $385 million in the prior year period. Net income attributable to Quest Diagnostics for the quarter was $296 million, an increase of 13.1% from $262 million in the third quarter of 2024. Cash provided by operations was $563 million, up 57.4% from $356 million in the prior year quarter. Capital expenditures for the quarter totaled $144 million, compared to $106 million in the third quarter of 2024. Year-to-date cash provided by operations increased 63.1% to $1.42 billion from $870 million in the same period last year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL1sBJxF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","BK4567","LU1854103824.USD","BK4588","BK4583","BK4196","BK4585","DGX"],"gpt_icon":0},{"id":"2577829144","title":"Quest Diagnostics Outlook FY Adjusted EPS USD 9.76-9.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2577829144","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577829144?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:45","pubTimestamp":1761043501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nPLX7ED46A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","LU1854103824.USD","BK4567","BK4583","BK4196","DGX","LU1854104046.USD"],"gpt_icon":0},{"id":"2577829129","title":"Quest Diagnostics Outlook FY EPS USD 8.58-8.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2577829129","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577829129?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:45","pubTimestamp":1761043501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nPLX7ED46A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","LU1854104046.USD","BK4583","DGX","BK4196","BK4567","LU1854103824.USD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":79,"code":"91000000","status":"200"}]}}